Download PDF
Semin Neurol 2020; 40(02): 201-210
DOI: 10.1055/s-0040-1708504
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Rasmussen Encephalitis: An Update

Karla C. Cay-Martinez
1   Department of Neurology, Columbia University Irving Medical Center, New York, New York
,
Richard A. Hickman
2   Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York
,
Guy M. McKhann II
3   Department of Neurosurgery, Columbia University Irving Medical Center, New York, New York
,
Frank A. Provenzano
1   Department of Neurology, Columbia University Irving Medical Center, New York, New York
4   Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York
,
Tristan T. Sands 
1   Department of Neurology, Columbia University Irving Medical Center, New York, New York
5   Institute for Genomic Medicine, Columbia University Irving Medical Center, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
17 March 2020 (online)

    Permissions and Reprints

Abstract

Rasmussen encephalitis (RE) is a rare, devastating, progressive pediatric epilepsy. First described 60 years ago, RE continues to present challenges in diagnosis and management. RE causes a unilateral focal epilepsy in children that typically becomes medically refractory, results in significant hemiparesis, and causes progressive cognitive decline. The etiology is a cell-mediated immune attack on one cerebral hemisphere, though the inciting antigen remains unknown. While the underlying histopathology is unilateral and RE is described as “unihemispheric,” studies have demonstrated (1) atrophy of the unaffected hemisphere, (2) electroencephalographic abnormalities (slowing and spikes) in the unaffected hemisphere, and (3) cognitive decline referable to the unaffected hemisphere. These secondary contralateral effects likely reflect the impact of uncontrolled epileptic activity (i.e., epileptic encephalopathy). Hemispheric disconnection (HD) renders 70 to 80% of patients seizure free. While it has the potential to limit the influence of seizures and abnormal electrical activity emanating from the pathological hemisphere, HD entails hemiparesis and hemianopia, as well as aphasia for patients with dominant HD. With the recent expansion of available immunomodulatory therapies, there has been interest in identifying an alternative to HD, though evidence for disease modification is limited to date. We review what is known and what remains unknown about RE.

Keywords

Rasmussen Encephalitis - epilepsia partialis continua - epileptic encephalopathy
 

  • References

  • 1 Rasmussen T, Olszewski J, Lloydsmith D. Focal seizures due to chronic localized encephalitis. Neurology 1958; 8 (06) 435-445
    CrossrefPubMedGoogle Scholar
  • 2 Bien CG, Tiemeier H, Sassen R. , et al. Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia 2013; 54 (03) 543-550
    CrossrefPubMedGoogle Scholar
  • 3 Bhatjiwale MG, Polkey C, Cox TC, Dean A, Deasy N. Rasmussen's encephalitis: neuroimaging findings in 21 patients with a closer look at the basal ganglia. Pediatr Neurosurg 1998; 29 (03) 142-148
    CrossrefPubMedGoogle Scholar
  • 4 Granata T, Gobbi G, Spreafico R. , et al. Rasmussen's encephalitis: early characteristics allow diagnosis. Neurology 2003; 60 (03) 422-425
    CrossrefPubMedGoogle Scholar
  • 5 Bien CG, Widman G, Urbach H. , et al. The natural history of Rasmussen's encephalitis. Brain 2002; 125 (Pt 8): 1751-1759
    CrossrefPubMedGoogle Scholar
  • 6 Rajesh B, Kesavadas C, Ashalatha R, Thomas B. Putaminal involvement in Rasmussen encephalitis. Pediatr Radiol 2006; 36 (08) 816-822
    CrossrefPubMedGoogle Scholar
  • 7 Ambrosino P, Freri E, Castellotti B. , et al. Kv7.3 Compound heterozygous variants in early onset encephalopathy reveal additive contribution of C-terminal residues to PIP2-dependent K+ channel gating. Mol Neurobiol 2018; 55 (08) 7009-7024
    CrossrefPubMedGoogle Scholar
  • 8 Longaretti F, Dunkley C, Varadkar S, Vargha-Khadem F, Boyd SG, Cross JH. Evolution of the EEG in children with Rasmussen's syndrome. Epilepsia 2012; 53 (09) 1539-1545
    CrossrefPubMedGoogle Scholar
  • 9 Rudebeck SR, Shavel-Jessop S, Varadkar S. , et al. Pre- and postsurgical cognitive trajectories and quantitative MRI changes in Rasmussen syndrome. Epilepsia 2018; 59 (06) 1210-1219
    CrossrefPubMedGoogle Scholar
  • 10 Engel Jr J. ; International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42 (06) 796-803
    CrossrefPubMedGoogle Scholar
  • 11 Chiapparini L, Granata T, Farina L. , et al. Diagnostic imaging in 13 cases of Rasmussen's encephalitis: can early MRI suggest the diagnosis?. Neuroradiology 2003; 45 (03) 171-183
    CrossrefPubMedGoogle Scholar
  • 12 Wagner J, Schoene-Bake JC, Bien CG, Urbach H, Elger CE, Weber B. Automated 3D MRI volumetry reveals regional atrophy differences in Rasmussen encephalitis. Epilepsia 2012; 53 (04) 613-621
    CrossrefPubMedGoogle Scholar
  • 13 Yamazaki E, Takahashi Y, Akasaka N, Fujiwara T, Inoue Y. Temporal changes in brain MRI findings in Rasmussen syndrome. Epileptic Disord 2011; 13 (03) 229-239
    PubMedGoogle Scholar
  • 14 Wang ZI, Krishnan B, Shattuck DW. , et al; Pediatric Imaging, Neurocognition and Genetics Study. Automated MRI volumetric analysis in patients with Rasmussen syndrome. AJNR Am J Neuroradiol 2016; 37 (12) 2348-2355
    CrossrefPubMedGoogle Scholar
  • 15 Bien CG, Urbach H, Deckert M. , et al. Diagnosis and staging of Rasmussen's encephalitis by serial MRI and histopathology. Neurology 2002; 58 (02) 250-257
    CrossrefPubMedGoogle Scholar
  • 16 Lee JS, Juhász C, Kaddurah AK, Chugani HT. Patterns of cerebral glucose metabolism in early and late stages of Rasmussen's syndrome. J Child Neurol 2001; 16 (11) 798-805
    CrossrefPubMedGoogle Scholar
  • 17 Kuki I, Matsuda K, Kubota Y. , et al. Functional neuroimaging in Rasmussen syndrome. Epilepsy Res 2018; 140: 120-127
    CrossrefPubMedGoogle Scholar
  • 18 Larionov S, König R, Urbach H, Sassen R, Elger CE, Bien CG. MRI brain volumetry in Rasmussen encephalitis: the fate of affected and “unaffected” hemispheres. Neurology 2005; 64 (05) 885-887
    CrossrefPubMedGoogle Scholar
  • 19 Krueger CE, Dean DL, Rosen HJ. , et al. Longitudinal rates of lobar atrophy in frontotemporal dementia, semantic dementia, and Alzheimer's disease. Alzheimer Dis Assoc Disord 2010; 24 (01) 43-48
    CrossrefPubMedGoogle Scholar
  • 20 David B, Prillwitz CC, Hoppe C. , et al. Morphometric MRI findings challenge the concept of the “unaffected” hemisphere in Rasmussen encephalitis. Epilepsia 2019; 60 (05) e40-e46
    PubMedGoogle Scholar
  • 21 Tobias SM, Robitaille Y, Hickey WF, Rhodes CH, Nordgren R, Andermann F. Bilateral Rasmussen encephalitis: postmortem documentation in a five-year-old. Epilepsia 2003; 44 (01) 127-130
    CrossrefPubMedGoogle Scholar
  • 22 Pardo CA, Vining EP, Guo L, Skolasky RL, Carson BS, Freeman JM. The pathology of Rasmussen syndrome: stages of cortical involvement and neuropathological studies in 45 hemispherectomies. Epilepsia 2004; 45 (05) 516-526
    CrossrefPubMedGoogle Scholar
  • 23 Takei H, Wilfong A, Malphrus A. , et al. Dual pathology in Rasmussen's encephalitis: a study of seven cases and review of the literature. Neuropathology 2010; 30 (04) 381-391
    PubMedGoogle Scholar
  • 24 Rogers SW, Andrews PI, Gahring LC. , et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994; 265 (5172): 648-651
    CrossrefPubMedGoogle Scholar
  • 25 Wiendl H, Bien CG, Bernasconi P. , et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 2001; 57 (08) 1511-1514
    CrossrefPubMedGoogle Scholar
  • 26 Watson R, Jiang Y, Bermudez I. , et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 2004; 63 (01) 43-50
    CrossrefPubMedGoogle Scholar
  • 27 Bien CG, Bauer J, Deckwerth TL. , et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol 2002; 51 (03) 311-318
    CrossrefPubMedGoogle Scholar
  • 28 Bauer J, Bien CG, Lassmann H. Rasmussen's encephalitis: a role for autoimmune cytotoxic T lymphocytes. Curr Opin Neurol 2002; 15 (02) 197-200
    CrossrefPubMedGoogle Scholar
  • 29 Li Y, Uccelli A, Laxer KD. , et al. Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. J Immunol 1997; 158 (03) 1428-1437
    PubMedGoogle Scholar
  • 30 Schwab N, Bien CG, Waschbisch A. , et al. CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain 2009; 132 (Pt 5): 1236-1246
    CrossrefPubMedGoogle Scholar
  • 31 Schneider-Hohendorf T, Mohan H, Bien CG. , et al. CD8(+) T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. Nat Commun 2016; 7: 11153
    CrossrefPubMedGoogle Scholar
  • 32 Al Nimer F, Jelcic I, Kempf C. , et al. Phenotypic and functional complexity of brain-infiltrating T cells in Rasmussen encephalitis. Neurol Neuroimmunol Neuroinflamm 2017; 5 (01) e419
    PubMedGoogle Scholar
  • 33 Bien CG, Granata T, Antozzi C. , et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 2005; 128 (Pt 3): 454-471
    CrossrefPubMedGoogle Scholar
  • 34 Derry C, Dale RC, Thom M, Miller DH, Giovannoni G. Unihemispheric cerebral vasculitis mimicking Rasmussen's encephalitis. Neurology 2002; 58 (02) 327-328
    CrossrefPubMedGoogle Scholar
  • 35 Olson HE, Lechpammer M, Prabhu SP. , et al. Clinical application and evaluation of the Bien diagnostic criteria for Rasmussen encephalitis. Epilepsia 2013; 54 (10) 1753-1760
    CrossrefPubMedGoogle Scholar
  • 36 Hart YM, Cortez M, Andermann F. , et al. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 1994; 44 (06) 1030-1036
    CrossrefPubMedGoogle Scholar
  • 37 Chinchilla D, Dulac O, Robain O. , et al. Reappraisal of Rasmussen's syndrome with special emphasis on treatment with high doses of steroids. J Neurol Neurosurg Psychiatry 1994; 57 (11) 1325-1333
    CrossrefPubMedGoogle Scholar
  • 38 Andrews PI, Dichter MA, Berkovic SF, Newton MR, McNamara JO. Plasmapheresis in Rasmussen's encephalitis. Neurology 1996; 46 (01) 242-246
    CrossrefPubMedGoogle Scholar
  • 39 Antozzi C, Granata T, Aurisano N. , et al. Long-term selective IgG immuno-adsorption improves Rasmussen's encephalitis. Neurology 1998; 51 (01) 302-305
    CrossrefPubMedGoogle Scholar
  • 40 Granata T, Fusco L, Gobbi G. , et al. Experience with immunomodulatory treatments in Rasmussen's encephalitis. Neurology 2003; 61 (12) 1807-1810
    CrossrefPubMedGoogle Scholar
  • 41 Bahi-Buisson N, Villanueva V, Bulteau C. , et al. Long term response to steroid therapy in Rasmussen encephalitis. Seizure 2007; 16 (06) 485-492
    CrossrefPubMedGoogle Scholar
  • 42 Bien CG, Gleissner U, Sassen R, Widman G, Urbach H, Elger CE. An open study of tacrolimus therapy in Rasmussen encephalitis. Neurology 2004; 62 (11) 2106-2109
    CrossrefPubMedGoogle Scholar
  • 43 Cho SM, Zeft A, Knight EP, Kotagal P, Wyllie E, Moosa ANV. Refractory status epilepticus secondary to atypical Rasmussen encephalitis successfully managed with aggressive immunotherapy. Neurol Clin Pract 2017; 7 (01) e5-e8
    CrossrefPubMedGoogle Scholar
  • 44 Liba Z, Muthaffar O, Tang J. , et al. Rasmussen encephalitis: response to early immunotherapy in a case of immune-mediated encephalitis. Neurol Neuroimmunol Neuroinflamm 2015; 2 (02) e69
    CrossrefPubMedGoogle Scholar
  • 45 Liba Z, Sedlacek P, Sebronova V. , et al. Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitis. Neurol Neuroimmunol Neuroinflamm 2017; 4 (04) e354
    CrossrefPubMedGoogle Scholar
  • 46 Thilo B, Stingele R, Knudsen K. , et al. A case of Rasmussen encephalitis treated with rituximab. Nat Rev Neurol 2009; 5 (08) 458-462
    PubMedGoogle Scholar
  • 47 Lagarde S, Villeneuve N, Trébuchon A. , et al. Anti-tumor necrosis factor alpha therapy (adalimumab) in Rasmussen's encephalitis: an open pilot study. Epilepsia 2016; 57 (06) 956-966
    CrossrefPubMedGoogle Scholar
  • 48 Kebir H, Carmant L, Fontaine F. , et al. Humanized mouse model of Rasmussen's encephalitis supports the immune-mediated hypothesis. J Clin Invest 2018; 128 (05) 2000-2009
    CrossrefPubMedGoogle Scholar
  • 49 Bien CG, Schramm J. Treatment of Rasmussen encephalitis half a century after its initial description: promising prospects and a dilemma. Epilepsy Res 2009; 86 (2-3): 101-112
    CrossrefPubMedGoogle Scholar
  • 50 Baumgartner JE, Blount JP, Blauwblomme T, Chandra PS. Technical descriptions of four hemispherectomy approaches: from the Pediatric Epilepsy Surgery Meeting at Gothenburg 2014. Epilepsia 2017; 58 (Suppl. 01) 46-55
    CrossrefPubMedGoogle Scholar
  • 51 Skirrow C, Cross JH, Owens R. , et al. Determinants of IQ outcome after focal epilepsy surgery in childhood: a longitudinal case-control neuroimaging study. Epilepsia 2019; 60 (05) 872-884
    CrossrefPubMedGoogle Scholar
  • 52 Flint AE, Waterman M, Bowmer G, Vadlamani G, Chumas P, Morrall MCHJ. Neuropsychological outcomes following paediatric temporal lobe surgery for epilepsies: evidence from a systematic review. Seizure 2017; 52: 89-116
    CrossrefPubMedGoogle Scholar
  • 53 Baldeweg T, Skirrow C. Long-term cognitive outcomes after epilepsy surgery in children. In: Malgren K, Cross H, Baxendale S. , ed. Long-Term Outcomes of Epilepsy Surgery in Adults and Children. . Cham, Switzerland: Springer; 2015: 85-101
    Crossref
  • 54 Jonas R, Nguyen S, Hu B. , et al. Cerebral hemispherectomy: hospital course, seizure, developmental, language, and motor outcomes. Neurology 2004; 62 (10) 1712-1721
    CrossrefPubMedGoogle Scholar
  • 55 Basheer SN, Connolly MB, Lautzenhiser A, Sherman EM, Hendson G, Steinbok P. Hemispheric surgery in children with refractory epilepsy: seizure outcome, complications, and adaptive function. Epilepsia 2007; 48 (01) 133-140
    PubMedGoogle Scholar
  • 56 Thomas SG, Daniel RT, Chacko AG, Thomas M, Russell PS. Cognitive changes following surgery in intractable hemispheric and sub-hemispheric pediatric epilepsy. Childs Nerv Syst 2010; 26 (08) 1067-1073
    CrossrefPubMedGoogle Scholar
  • 57 Granata T, Matricardi S, Ragona F. , et al. Hemispherotomy in Rasmussen encephalitis: long-term outcome in an Italian series of 16 patients. Epilepsy Res 2014; 108 (06) 1106-1119
    CrossrefPubMedGoogle Scholar
  • 58 Boatman D, Freeman J, Vining E. , et al. Language recovery after left hemispherectomy in children with late-onset seizures. Ann Neurol 1999; 46 (04) 579-586
    CrossrefPubMedGoogle Scholar
  • 59 Pulsifer MB, Brandt J, Salorio CF, Vining EP, Carson BS, Freeman JM. The cognitive outcome of hemispherectomy in 71 children. Epilepsia 2004; 45 (03) 243-254
    CrossrefPubMedGoogle Scholar
  • 60 Bulteau C, Grosmaitre C, Save-Pédebos J. , et al. Language recovery after left hemispherotomy for Rasmussen encephalitis. Epilepsy Behav 2015; 53: 51-57
    CrossrefPubMedGoogle Scholar
  • 61 Caplan R, Curtiss S, Chugani HT, Vinters HV. Pediatric Rasmussen encephalitis: social communication, language, PET and pathology before and after hemispherectomy. Brain Cogn 1996; 32 (01) 45-66
    CrossrefPubMedGoogle Scholar
  • 62 Hartman AL, Cross JH. Timing of surgery in Rasmussen syndrome: is patience a virtue?. Epilepsy Curr 2014; 14 (01) , Suppl): 8-11
    CrossrefPubMedGoogle Scholar